Bayer boss blasts Brexit, protectionism and emotion-driven politics

23 February 2017

The chief executive of German pharma major Bayer (BAYN: DE) did not hold back in expressing his views on the year’s politics developments as he presented his company’s annual results for the first time.

Werner Baumann (pictured above), who has been in Bayer’s top job since May 2016, said the company remained optimistic about its economic future as he predicted a low to mid-single-digit percentage rise in revenue for 2017.

But he stressed during the press conference at the company’s Leverkusen headquarters: “Our long-term success is highly dependent on the political and societal environment in which we operate.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK